molecule
stringlengths 1
990
| caption
stringlengths 5
2.09k
|
|---|---|
CCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | The molecule is a stabilizing cytochrome oxidase that impacts both aging and diabetic heart disease. The molecule is a cholesterol translocation and a stabilizing mitochondrial structure, impacting both barth syndrome and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation and apoptosis, and it impacts tangier disease. |
CCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | The molecule is a proton trap for oxidative phosphorylation and stabilizing mitochondrial structure, and it impacts non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase that impacts both aging and barth syndrome. The molecule is a cholesterol translocation and a apoptosis, impacting both tangier disease and diabetic heart disease. |
CCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | The molecule is a cholesterol translocation that impacts non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, apoptosis, stabilizing cytochrome oxidase. It impacts diabetic heart disease, tangier disease, barth syndrome, and aging. |
CCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | The molecule is a stabilizing cytochrome oxidase that impacts diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation that impacts tangier disease, barth syndrome, and non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure, a apoptosis, and a cholesterol translocation, and it impacts aging. |
CCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | The molecule is a stabilizing mitochondrial structure and a proton trap for oxidative phosphorylation, impacting both non-alcoholic fatty liver disease and tangier disease. The molecule is a apoptosis that impacts barth syndrome, aging, and diabetic heart disease. The molecule is both a cholesterol translocation and a stabilizing cytochrome oxidase. |
CCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCCCC(C)C | The molecule is a energy storage, fat storage, membrane stabilizer that impacts metabolic syndrome, cardiovascular disease, and thyroxine treatment. The molecule is a energy source and inflammatory, and it impacts pancreatitis. The molecule is a nutrient that impacts atherosclerosis, cancer, and obesity. |
CCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCCCC(C)C | The molecule is a inflammatory and a membrane stabilizer that impacts thyroxine treatment, obesity, and atherosclerosis. The molecule is a nutrient, fat storage, energy storage that impacts cardiovascular disease and metabolic syndrome. The molecule is a energy source that affects cancer by impacting pancreatitis. |
CCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCCCC(C)C | The molecule is a thyroxine treatment and fat storage, and it impacts atherosclerosis. The molecule is a membrane stabilizer, a energy storage, and a nutrient, and it impacts obesity. The molecule is a energy source and inflammatory, affecting cancer, and impacting metabolic syndrome, cardiovascular disease, and pancreatitis. |
CCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCCCC(C)C | The molecule is a fat storage, energy source, and inflammatory that has an effect on cancer and impacts both atherosclerosis and pancreatitis. The molecule is a energy storage and membrane stabilizer, and it impacts obesity. The molecule is a nutrient and belongs to the thyroxine treatment class of molecules, impacting both cardiovascular disease and metabolic syndrome. |
CCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCCCC(C)C | The molecule is a nutrient, fat storage, and energy storage that has an effect on cancer and impacts both metabolic syndrome and pancreatitis. The molecule is a membrane stabilizer and energy source, belonging to the thyroxine treatment class of molecules, and impacts atherosclerosis, cardiovascular disease, and obesity. The molecule is a inflammatory. |
CC/C=C\C/C=C\C/C=C\C/C=C\CCCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCC | The molecule is a nutrient, thyroxine treatment, fat storage that impacts metabolic syndrome, pancreatitis, and atherosclerosis. It impacts cardiovascular disease. |
CC/C=C\C/C=C\C/C=C\C/C=C\CCCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCC | It impacts cardiovascular disease, pancreatitis, and atherosclerosis. The molecule is a nutrient and fat storage, belonging to the thyroxine treatment class of molecules, and impacts metabolic syndrome. |
CC/C=C\C/C=C\C/C=C\C/C=C\CCCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCC | The molecule is thyroxine treatment and it impacts both cardiovascular disease and pancreatitis. The molecule is a nutrient and a fat storage, impacting both metabolic syndrome and atherosclerosis. |
CC/C=C\C/C=C\C/C=C\C/C=C\CCCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCC | The molecule is a nutrient that impacts both pancreatitis and metabolic syndrome. The molecule is a fat storage and a thyroxine treatment, impacting both atherosclerosis and cardiovascular disease. |
CC/C=C\C/C=C\C/C=C\C/C=C\CCCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCC | The molecule is a thyroxine treatment that impacts both atherosclerosis and pancreatitis. The molecule is a nutrient and a fat storage, impacting both cardiovascular disease and metabolic syndrome. |
CCCCn1cc2c(n1)c(Cl)nc1ccccc12 | The molecule is anti body. |
CCCCn1cc2c(n1)c(Cl)nc1ccccc12 | The molecule is anti body. |
CCCCn1cc2c(n1)c(Cl)nc1ccccc12 | It belongs to the anti body class of molecules. |
CCCCn1cc2c(n1)c(Cl)nc1ccccc12 | The molecule is a anti body. |
CCCCn1cc2c(n1)c(Cl)nc1ccccc12 | It belongs to the anti body class of molecules. |
CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCC(C)C | It impacts non-alcoholic fatty liver disease, diabetic heart disease, and barth syndrome. The molecule is a stabilizing mitochondrial structure and stabilizing cytochrome oxidase, and it impacts tangier disease. The molecule is a cholesterol translocation, a apoptosis, and a proton trap for oxidative phosphorylation, and it impacts aging. |
CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCC(C)C | The molecule is a cholesterol translocation and a stabilizing mitochondrial structure, impacting both diabetic heart disease and barth syndrome. The molecule is a proton trap for oxidative phosphorylation, apoptosis, stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, tangier disease, and aging. |
CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCC(C)C | The molecule is a stabilizing mitochondrial structure that impacts both barth syndrome and tangier disease. The molecule is a stabilizing cytochrome oxidase that impacts both non-alcoholic fatty liver disease and aging. The molecule is a proton trap for oxidative phosphorylation, a cholesterol translocation, and a apoptosis, and it impacts diabetic heart disease. |
CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCC(C)C | The molecule is a cholesterol translocation that impacts aging. The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase, impacting both tangier disease and non-alcoholic fatty liver disease. The molecule is a apoptosis and a stabilizing mitochondrial structure, impacting both diabetic heart disease and barth syndrome. |
CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCC(C)C | The molecule is a proton trap for oxidative phosphorylation, a stabilizing mitochondrial structure, and a cholesterol translocation, and it impacts non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase that impacts tangier disease, diabetic heart disease, and aging. The molecule is a apoptosis that impacts barth syndrome. |
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC | The molecule is a stabilizing cytochrome oxidase that impacts both barth syndrome and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation and stabilizing mitochondrial structure, and it impacts aging. The molecule is a cholesterol translocation and a apoptosis, impacting both tangier disease and diabetic heart disease. |
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC | The molecule is a stabilizing mitochondrial structure and a apoptosis that impacts tangier disease, diabetic heart disease, and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts aging and barth syndrome. |
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC | The molecule is a stabilizing cytochrome oxidase and cholesterol translocation, and it impacts non-alcoholic fatty liver disease. The molecule is a apoptosis that impacts barth syndrome, diabetic heart disease, and aging. The molecule is a stabilizing mitochondrial structure and proton trap for oxidative phosphorylation, and it impacts tangier disease. |
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC | The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, apoptosis, proton trap for oxidative phosphorylation. The molecule is a stabilizing mitochondrial structure that impacts aging, non-alcoholic fatty liver disease, diabetic heart disease, and tangier disease. It impacts barth syndrome. |
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC | The molecule is a cholesterol translocation that impacts tangier disease. It impacts barth syndrome, diabetic heart disease, aging, and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation, apoptosis, stabilizing cytochrome oxidase, stabilizing mitochondrial structure. |
Cn1ccc2c(-c3ccc(Nc4ccc(S(C)(=O)=O)cn4)c4c3CNC4=O)ccnc21 | It belongs to the hpk1 antagonist class of molecules. |
Cn1ccc2c(-c3ccc(Nc4ccc(S(C)(=O)=O)cn4)c4c3CNC4=O)ccnc21 | The molecule is a hpk1 antagonist. |
Cn1ccc2c(-c3ccc(Nc4ccc(S(C)(=O)=O)cn4)c4c3CNC4=O)ccnc21 | It belongs to the hpk1 antagonist class of molecules. |
Cn1ccc2c(-c3ccc(Nc4ccc(S(C)(=O)=O)cn4)c4c3CNC4=O)ccnc21 | It belongs to the hpk1 antagonist class of molecules. |
Cn1ccc2c(-c3ccc(Nc4ccc(S(C)(=O)=O)cn4)c4c3CNC4=O)ccnc21 | It belongs to the hpk1 antagonist class of molecules. |
CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | The molecule is a stabilizing mitochondrial structure and a apoptosis that impacts tangier disease, aging, and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, cholesterol translocation that impacts barth syndrome and diabetic heart disease. |
CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | The molecule is a apoptosis, cholesterol translocation, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts barth syndrome and tangier disease. The molecule is a stabilizing cytochrome oxidase that impacts diabetic heart disease, non-alcoholic fatty liver disease, and aging. |
CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts tangier disease, diabetic heart disease, and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation and a apoptosis, impacting both aging and barth syndrome. |
CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | The molecule is a stabilizing mitochondrial structure that impacts barth syndrome, aging, diabetic heart disease, and non-alcoholic fatty liver disease. The molecule is a apoptosis, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, cholesterol translocation that impacts tangier disease. |
CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | The molecule is a stabilizing cytochrome oxidase that impacts both diabetic heart disease and barth syndrome. The molecule is a apoptosis, a cholesterol translocation, and a stabilizing mitochondrial structure, and it impacts tangier disease. The molecule is a proton trap for oxidative phosphorylation that impacts both aging and non-alcoholic fatty liver disease. |
CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | The molecule is a fat storage, inflammatory, membrane stabilizer that impacts cardiovascular disease and cancer. The molecule is a energy storage and energy source, belonging to the thyroxine treatment class of molecules, and it impacts both atherosclerosis and obesity. The molecule is a nutrient that impacts both pancreatitis and metabolic syndrome. |
CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | The molecule is both a energy source and a energy storage. The molecule is a nutrient and a membrane stabilizer, which has an effect on cancer and impacts both pancreatitis and thyroxine treatment. The molecule is a inflammatory and a fat storage that impacts cardiovascular disease, metabolic syndrome, obesity, and atherosclerosis. |
CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | The molecule is a membrane stabilizer that impacts both cardiovascular disease and metabolic syndrome. The molecule is a energy storage, fat storage, inflammatory, energy source that impacts atherosclerosis. The molecule is a nutrient and a thyroxine treatment, which has an effect on cancer and impacts both obesity and pancreatitis. |
CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | The molecule is a inflammatory and membrane stabilizer, and it impacts atherosclerosis. The molecule is a energy source that impacts metabolic syndrome, cancer, cardiovascular disease, and pancreatitis. The molecule is a energy storage, nutrient, fat storage that belongs to the thyroxine treatment class of molecules and impacts obesity. |
CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | It impacts obesity. The molecule is a nutrient, energy source, membrane stabilizer that impacts pancreatitis, metabolic syndrome, and cardiovascular disease. The molecule is a fat storage, thyroxine treatment, inflammatory, energy storage that impacts cancer and atherosclerosis. |
CCCOc1c(OCCn2ccnc2)cc(C2CCC(c3cc(OC)c(OC)c(OC)c3)O2)cc1S(=O)(=O)CC(C)O | The molecule is a platelet aggregation inhibitor and belongs to the paf antagonist class of molecules. |
CCCOc1c(OCCn2ccnc2)cc(C2CCC(c3cc(OC)c(OC)c(OC)c3)O2)cc1S(=O)(=O)CC(C)O | The molecule is a platelet aggregation inhibitor and belongs to the paf antagonist class of molecules. |
CCCOc1c(OCCn2ccnc2)cc(C2CCC(c3cc(OC)c(OC)c(OC)c3)O2)cc1S(=O)(=O)CC(C)O | The molecule is both a platelet aggregation inhibitor and a paf antagonist. |
CCCOc1c(OCCn2ccnc2)cc(C2CCC(c3cc(OC)c(OC)c(OC)c3)O2)cc1S(=O)(=O)CC(C)O | The molecule is both a platelet aggregation inhibitor and a paf antagonist. |
CCCOc1c(OCCn2ccnc2)cc(C2CCC(c3cc(OC)c(OC)c(OC)c3)O2)cc1S(=O)(=O)CC(C)O | The molecule is a platelet aggregation inhibitor and belongs to the paf antagonist class of molecules. |
C=CC(=O)N1CCCC(n2cc(Nc3ncc(C(N)=O)c(Nc4c(C)cc(C(=O)NC5CCC5)cc4OC)n3)cn2)C1 | The molecule is a jak inhibitor. |
C=CC(=O)N1CCCC(n2cc(Nc3ncc(C(N)=O)c(Nc4c(C)cc(C(=O)NC5CCC5)cc4OC)n3)cn2)C1 | The molecule is a jak inhibitor. |
C=CC(=O)N1CCCC(n2cc(Nc3ncc(C(N)=O)c(Nc4c(C)cc(C(=O)NC5CCC5)cc4OC)n3)cn2)C1 | The molecule is a jak inhibitor. |
C=CC(=O)N1CCCC(n2cc(Nc3ncc(C(N)=O)c(Nc4c(C)cc(C(=O)NC5CCC5)cc4OC)n3)cn2)C1 | The molecule is a jak inhibitor. |
C=CC(=O)N1CCCC(n2cc(Nc3ncc(C(N)=O)c(Nc4c(C)cc(C(=O)NC5CCC5)cc4OC)n3)cn2)C1 | The molecule is a jak inhibitor. |
CCCC/C=C\CCCCCCCC(=O)OC[C@H](CO)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | It impacts insulin resistance. |
CCCC/C=C\CCCCCCCC(=O)OC[C@H](CO)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | It impacts insulin resistance. |
CCCC/C=C\CCCCCCCC(=O)OC[C@H](CO)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | It impacts insulin resistance. |
CCCC/C=C\CCCCCCCC(=O)OC[C@H](CO)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | It impacts insulin resistance. |
CCCC/C=C\CCCCCCCC(=O)OC[C@H](CO)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | It impacts insulin resistance. |
OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O | The molecule is a flavoring agent, a nutrient, floral, cinnamon, and spicy. |
OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O | The molecule is a flavoring agent, a nutrient, cinnamon, floral, and spicy. |
OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O | The molecule is a nutrient, a flavoring agent, spicy, cinnamon, and floral. |
OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O | The molecule is a flavoring agent. The molecule is a nutrient, floral, spicy, and cinnamon. |
OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O | The molecule is a flavoring agent, a nutrient, cinnamon, floral, and spicy. |
COC(=O)C(=Cc1cncc(Br)c1C)N=[N+]=[N-] | The molecule is diabetes treatment. |
COC(=O)C(=Cc1cncc(Br)c1C)N=[N+]=[N-] | It impacts diabetes treatment. |
COC(=O)C(=Cc1cncc(Br)c1C)N=[N+]=[N-] | The molecule is a diabetes treatment. |
COC(=O)C(=Cc1cncc(Br)c1C)N=[N+]=[N-] | It impacts diabetes treatment. |
COC(=O)C(=Cc1cncc(Br)c1C)N=[N+]=[N-] | The molecule is diabetes treatment. |
O=C(O)c1cn(Cc2ccccc2Sc2ccc(Cl)cc2)c2cc(Br)cnc2c1=O | It belongs to the anti viral class of molecules. |
O=C(O)c1cn(Cc2ccccc2Sc2ccc(Cl)cc2)c2cc(Br)cnc2c1=O | The molecule is a anti viral. |
O=C(O)c1cn(Cc2ccccc2Sc2ccc(Cl)cc2)c2cc(Br)cnc2c1=O | The molecule is anti viral. |
O=C(O)c1cn(Cc2ccccc2Sc2ccc(Cl)cc2)c2cc(Br)cnc2c1=O | The molecule is anti viral. |
O=C(O)c1cn(Cc2ccccc2Sc2ccc(Cl)cc2)c2cc(Br)cnc2c1=O | It belongs to the anti viral class of molecules. |
CCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCC | The molecule is a apoptosis and a stabilizing mitochondrial structure, impacting both tangier disease and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation, cholesterol translocation, stabilizing cytochrome oxidase that impacts aging, barth syndrome, and non-alcoholic fatty liver disease. |
CCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCC | The molecule is a cholesterol translocation and a apoptosis, impacting both barth syndrome and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase and a stabilizing mitochondrial structure, impacting both tangier disease and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation that impacts aging. |
CCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCC | The molecule is a apoptosis. The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation, impacting both diabetic heart disease and aging. The molecule is a proton trap for oxidative phosphorylation and a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, tangier disease, and barth syndrome. |
CCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCC | The molecule is a cholesterol translocation and a proton trap for oxidative phosphorylation, impacting both barth syndrome and tangier disease. The molecule is a stabilizing cytochrome oxidase and a stabilizing mitochondrial structure, impacting both aging and diabetic heart disease. The molecule is a apoptosis that impacts non-alcoholic fatty liver disease. |
CCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCC | The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts diabetic heart disease, barth syndrome, tangier disease, and aging. The molecule is a proton trap for oxidative phosphorylation, a apoptosis, and a stabilizing mitochondrial structure, and it impacts non-alcoholic fatty liver disease. |
O=C(NC(Cc1ccc(F)cc1)C(=O)N1CCCN(CCO)CC1)c1cc2cc(Cl)ncc2[nH]1 | The molecule is a glycogen phosphorylase inhibitor that impacts diabetes treatment. |
O=C(NC(Cc1ccc(F)cc1)C(=O)N1CCCN(CCO)CC1)c1cc2cc(Cl)ncc2[nH]1 | The molecule is both a diabetes treatment and a glycogen phosphorylase inhibitor. |
O=C(NC(Cc1ccc(F)cc1)C(=O)N1CCCN(CCO)CC1)c1cc2cc(Cl)ncc2[nH]1 | The molecule is a glycogen phosphorylase inhibitor that impacts diabetes treatment. |
O=C(NC(Cc1ccc(F)cc1)C(=O)N1CCCN(CCO)CC1)c1cc2cc(Cl)ncc2[nH]1 | The molecule is a glycogen phosphorylase inhibitor and is diabetes treatment. |
O=C(NC(Cc1ccc(F)cc1)C(=O)N1CCCN(CCO)CC1)c1cc2cc(Cl)ncc2[nH]1 | The molecule is both a glycogen phosphorylase inhibitor and a diabetes treatment. |
CC(=O)N1CCC(NC(=O)c2cccc3cnc(NC4CCC(O)CC4)nc23)CC1 | The molecule is both a type 2 diabetes treatment and a obesity treatment. The molecule is a jnk inhibitor. |
CC(=O)N1CCC(NC(=O)c2cccc3cnc(NC4CCC(O)CC4)nc23)CC1 | The molecule is a jnk inhibitor. The molecule is type 2 diabetes treatment and it impacts obesity treatment. |
CC(=O)N1CCC(NC(=O)c2cccc3cnc(NC4CCC(O)CC4)nc23)CC1 | The molecule is a obesity treatment and jnk inhibitor, and it impacts type 2 diabetes treatment. |
CC(=O)N1CCC(NC(=O)c2cccc3cnc(NC4CCC(O)CC4)nc23)CC1 | The molecule is a jnk inhibitor and belongs to the obesity treatment class of molecules, with the characteristic of being type 2 diabetes treatment. |
CC(=O)N1CCC(NC(=O)c2cccc3cnc(NC4CCC(O)CC4)nc23)CC1 | The molecule is a jnk inhibitor and a type 2 diabetes treatment, belonging to the obesity treatment class of molecules. |
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCC)OCCCCCCCCCCCCCCCCCC | The molecule is a nutrient, thyroxine treatment, fat storage that impacts pancreatitis, cardiovascular disease, and atherosclerosis. It impacts metabolic syndrome. |
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCC)OCCCCCCCCCCCCCCCCCC | The molecule is a thyroxine treatment and a nutrient that impacts cardiovascular disease, metabolic syndrome, atherosclerosis, and pancreatitis. The molecule is a fat storage. |
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCC)OCCCCCCCCCCCCCCCCCC | The molecule is both a fat storage and a nutrient. It impacts atherosclerosis, pancreatitis, metabolic syndrome, and cardiovascular disease, and the molecule is thyroxine treatment. |
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCC)OCCCCCCCCCCCCCCCCCC | It impacts both atherosclerosis and cardiovascular disease. The molecule is a thyroxine treatment, fat storage, nutrient that impacts pancreatitis and metabolic syndrome. |
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCC)OCCCCCCCCCCCCCCCCCC | The molecule is a nutrient and a fat storage, impacting both cardiovascular disease and pancreatitis. It impacts atherosclerosis, metabolic syndrome, and thyroxine treatment. |
CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCC(C)C | The molecule is a cholesterol translocation, apoptosis, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts aging and barth syndrome. The molecule is a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, tangier disease, and diabetic heart disease. |
CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCC(C)C | The molecule is a proton trap for oxidative phosphorylation that impacts diabetic heart disease, barth syndrome, and tangier disease. The molecule is a cholesterol translocation, stabilizing mitochondrial structure, apoptosis, stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease and aging. |
CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCC(C)C | The molecule is a cholesterol translocation. The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation, impacting both diabetic heart disease and aging. The molecule is a stabilizing mitochondrial structure and a apoptosis that impacts tangier disease, non-alcoholic fatty liver disease, and barth syndrome. |
CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCC(C)C | It impacts tangier disease, diabetic heart disease, and barth syndrome. The molecule is a cholesterol translocation and a stabilizing cytochrome oxidase, impacting both non-alcoholic fatty liver disease and aging. The molecule is a stabilizing mitochondrial structure, a proton trap for oxidative phosphorylation, and a apoptosis. |
CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCC(C)C | The molecule is a apoptosis and stabilizing cytochrome oxidase, and it impacts aging. The molecule is a stabilizing mitochondrial structure that impacts both non-alcoholic fatty liver disease and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation and a cholesterol translocation, impacting both tangier disease and barth syndrome. |